Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes.

ABSTRACT:

Background

Sodium glucose co-transporter type 2 inhibitors improve cardiovascular outcomes in people with type 2 diabetes, though mechanisms by which this occurs remain unclear.

Objectives

The purpose of this study was to evaluate empagliflozin's effect on whole body, cardiac, and renal sympathetic activity in people with type 2 diabetes and cardiovascular disease or high cardiovascular risk.

Methods

Adults with type 2 diabetes, randomized to 25 mg/day empagliflozin or placebo for 12 weeks, had norepinephrine (NE) spillover kinetics assessed during right heart catheterization. Endpoints were mean spillover rates at the end of treatment, adjusted for baseline (primary outcome whole-body spillover; secondary outcomes cardiac and renal spillovers).

Results

Of 15 p

SUBMITTER: Reutens AT 

PROVIDER: S-EPMC12639828 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature